tradingkey.logo

Journey Medical Corp

DERM
View Detailed Chart
8.350USD
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
220.21MMarket Cap
LossP/E TTM

Journey Medical Corp

8.350
0.0000.00%
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

-0.12%

1 Month

+15.65%

6 Months

+15.49%

Year to Date

+8.30%

1 Year

+67.00%

View Detailed Chart

TradingKey Stock Score of Journey Medical Corp

Currency: USD Updated: 2026-02-06

Key Insights

Journey Medical Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 70 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Journey Medical Corp's Score

Industry at a Glance

Industry Ranking
70 / 159
Overall Ranking
185 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Journey Medical Corp Highlights

StrengthsRisks
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.13M.
Undervalued
The company’s latest PE is -24.20, at a low 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 247.90K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.31.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
13.500
Target Price
+61.68%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Journey Medical Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Journey Medical Corp Info

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Ticker SymbolDERM
CompanyJourney Medical Corp
CEOMaraoui (Claude)
Websitehttps://journeymedicalcorp.com/
KeyAI